Sarah Dube, PharmD, Sana Mandal, PharmD, BCPS, Kaelyn C. Boss, PharmD, Thomas C. Pomfret, PharmD, MPH, BCPS, Caroline J. Alper, MD, Mark Tesell, PharmD, BCPS, Rachel Bacon, PharmD, MPH, Karen Clements, MPH, ScD, Kyle Semmel, PharmD1, Kimberly Lenz, PharmD, MBA, FAMCP1
1Massachusetts Executive Office of Health and Human Services, MassHealth
At the Academy of Managed Care Pharmacy Conference 2026 Annual Meeting, our pharmacy team presented the poster, “An Evaluation of Real-World Outcomes and Healthcare Costs Associated with Continuous Glucose Monitor (CGM) Use Among Patients with Non-Insulin-Treated Type 2 Diabetes Within a Medicaid Population.” The poster was a collaborative production with several colleagues from MassHealth.
The poster evaluated real-world outcomes and healthcare costs associated with continued glucose monitoring (CGM) use in adult patients with non-insulin-treated Type 2 diabetes. They found that CGM users, despite relatively high rates of adherence, experienced higher rates of diabetes-related acute care events and overall healthcare costs compared with non-CGM users. But event-related medical costs were higher in non-CGM users, suggesting more severe presentations and highlighting the value of earlier detection and management with CGM devices.